Implications of Altered Glutathione Metabolism in Aspirin-Induced Oxidative Stress and Mitochondrial Dysfunction in HepG2 Cells by Raza, Haider & John, Annie
Implications of Altered Glutathione Metabolism in
Aspirin-Induced Oxidative Stress and Mitochondrial
Dysfunction in HepG2 Cells
Haider Raza*, Annie John
Department of Biochemistry, Faculty of Medicine and Health Sciences, United Arab Emirates (UAE) University, Al Ain, United Arab Emirates
Abstract
We have previously reported that acetylsalicylic acid (aspirin, ASA) induces cell cycle arrest, oxidative stress and
mitochondrial dysfunction in HepG2 cells. In the present study, we have further elucidated that altered glutathione (GSH)-
redox metabolism in HepG2 cells play a critical role in ASA-induced cytotoxicity. Using selected doses and time point for
ASA toxicity, we have demonstrated that when GSH synthesis is inhibited in HepG2 cells by buthionine sulfoximine (BSO),
prior to ASA treatment, cytotoxicity of the drug is augmented. On the other hand, when GSH-depleted cells were treated
with N-acetyl cysteine (NAC), cytotoxicity/apoptosis caused by ASA was attenuated with a significant recovery in oxidative
stress, GSH homeostasis, DNA fragmentation and some of the mitochondrial functions. NAC treatment, however, had no
significant effects on the drug-induced inhibition of mitochondrial aconitase activity and ATP synthesis in GSH-depleted
cells. Our results have confirmed that aspirin increases apoptosis by increased reactive oxygen species production, loss of
mitochondrial membrane potential and inhibition of mitochondrial respiratory functions. These effects were further
amplified when GSH-depleted cells were treated with ASA. We have also shown that some of the effects of aspirin might be
associated with reduced GSH homeostasis, as treatment of cells with NAC attenuated the effects of BSO and aspirin. Our
results strongly suggest that GSH dependent redox homeostasis in HepG2 cells is critical in preserving mitochondrial
functions and preventing oxidative stress associated complications caused by aspirin treatment.
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Introduction
Inflammation induced response have been implicated in the
pathogenesis of numerous diseases including cancer. Increased
formation of inflammatory cytokines such as TNF-a, IL-1b and
others has been described in the pathophysiology of degenerative
diseases, infections and drug-induced toxicities [1], [2]. Arachi-
donic acid metabolism to prostaglandins by cyclooxygenase
(COX) is a key for initiation of many inflammatory responses
[3], [4]. Non-steroidal anti-inflammatory drugs (NSAIDs), includ-
ing aspirin (ASA) reduce inflammation by inhibiting the synthesis
of prostaglandins (PGs) and induce apoptosis in a variety of cancer
cells [5], [6], [7].Tumor cells are known to develop resistance
towards therapeutic drugs and irradiation due to inhibition of
apoptotic stimuli in these cells. NSAIDs have been suggested to
induce apoptosis in resistant tumor cells [8]. However, the precise
molecular mechanisms by which these compounds induce
apoptosis and promote antitumor action are not clearly under-
stood. The most important and best defined molecular target for
ASA is COX. However, there are multiple reports suggesting
several additional mechanisms of action, independent of their
ability to inhibit COX activity, that may contribute to its anti-
cancer and anti-inflammatory effects [9],[10],[11].There is little
information on the selectivity and specificity of NSAID-mediated
effects and therefore a better understanding of the molecular and
biochemical mechanisms for aspirin and other NSAIDs is essential
for therapeutic use of drugs in multiple disorders associated with
inflammation. Concerns about the selectivity of NSAIDs and
associated toxicity have limited the widespread use of this drug.
Recent epidemiological studies on humans and experimental
models in diabetes, cancer and cardiovascular diseases have
demonstrated that regular use of ASA alone or as an adjuvant may
improve the outcome of disease prevention/protection in favor of
benefit: risk ratio [11].
Aspirin has been shown to exert its cytotoxicity and anti-
inflammatory effects through multiple mechanisms of action that
may include generation of reactive oxygen species, increased
oxidative stress, mitochondrial dysfunction and induction of
apoptosis [6], [12], [13]. However, aspirin has also been shown
to protect endothelial cells from oxidative damage via nitric oxide/
cGMP pathway [14]. Aspirin has also been shown to protect
against acetaminophen-induced liver toxicity due to down
regulation of proinflammatory cytokines rather than COX-1
inhibition [15]. Alteration in innate immune response by Tlr9 and
the Nalp3 inflammasome in acetaminophen-induced hepatotox-
icity and induction of autophagy through the removal of damaged
mitochondria and oxidative stress may be the potential mecha-
nisms for aspirin-induced cytoprotection [15], [16]. Mitochondrial
oxidative stress and respiratory dysfunctions in cancer cells may,
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of apoptosis-inducing factors and proteins and subsequent
activation of the caspases [17], [18], [19]. A group of compounds,
termed ‘mitocans’, which target the mitochondrial structural
integrity and respiratory and thiol redox functions, are being
studied extensively, as they have a potential to be effective
therapeutic drugs against cancer [20], [21], [22]. Recently, we
have demonstrated that dose- and time-dependent ASA treatment
of HepG2 cells caused cell cycle arrest, increase in ROS
production, reduction in mitochondrial potential, and alterations
in mitochondrial redox and respiratory functions [23]. Based on
the mitochondrial toxicity in cancer cells, ASA may also be
classified as a potential ‘mitocan’. Our present hypothesis is that
compounds which can directly target mitochondrial function offer
the advantage of mitochondrial-mediated cell death independent
of upstream signaling molecules that are impaired in cancer
development, treatment and/or drug resistance. Therefore, in this
study, we have used human hepatoma HepG2 cancer cells, a
commonly used cell culture model, which has been treated with
buthionine sulfoximine (BSO), a GSH depleting agent and N-
acetylcysteine (NAC), a precursor of GSH synthesis, to study the
implications of altered glutathione metabolism in ASA-induced
oxidative stress, redox homeostasis and mitochondrial dysfunc-
tions.
Materials and Methods
Chemicals
Aspirin (acetylsalicylic acid, ASA), cytochrome c, reduced and
oxidized glutathione, (GSH and GSSG), 1-chloro 2,4-dinitroben-
zene (CDNB), cumene hydroperoxide, glutathione reductase, 5,59-
dithio bis-2-nitrobenzoic acid (DTNB), 2-thiobarbituric acid,
buthionine sulfoximine (BSO), N-acetylcysteine (NAC), NADH,
NADPH, coenzyme Q2, antimycin A, dodecyl maltoside and ATP
bioluminescent somatic cell assay kit were purchased from Sigma-
Aldrich Fine Chemicals (St Louis, MO, USA). 29,7 9- Dichloro-
fluorescein diacetate (DCFDA) was from Molecular Probes
(Eugene, OR, USA). Aconitase assay kit was procured from Oxis
International Inc. (Portland, OR, USA). Apoptosis detection kit
for flow cytometry was from BD Pharmingen (BD Biosciences, San
Jose, USA). Kits for caspase-3 and mitochondrial membrane
potential assays were purchased from R&D System, MN, USA.
HepG2 cells were purchased from American Type Culture
Collection (Manassas, VA, USA) and have been used for studies
in our recent publication [23]. Polyclonal antibodies against beta-
actin, caspase-3, PARP, cytochrome c, Bcl-2, Tom-40 and FITC-
conjugated secondary antibodies were purchased from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). Glutathione S-
transferase A4-4 (GSTA4-4) antibody was a generous gift from
Prof. Bengt Mannervik, Uppsala University, Stockholm, Sweden.
Reagents for cell culture and for SDS-PAGE and Western blot
analyses were purchased from Gibco BRL (Grand Island, NY,
USA) and from Bio Rad Laboratories (Richmond, CA, USA)
respectively.
HepG2 cell culture, treatment and cellular fractionation
HepG2 cells were grown in poly-L-lysine coated 75 cm
2 flasks
(,2.0–2.5610
6cells/ml) in DMEM medium supplemented with
1% nonessential amino acids, 2 mM glutamine, 10% heat
inactivated fetal bovine serum in the presence of 5% CO2–95%
air at 37uC as described before [23]. Cells were treated with 5 or
10 mmol/ml ASA (dissolved in 1 M Tris-HCl (pH 7.6) to a stock
solution of 1 M and adjusted to pH 7.45 with 4 N HCl) for
48 hours. Selection of dose and time points for the test compounds
were based on our previous publication [23] and literature search.
The GSH level was depleted in HepG2 cells by the treatment of
BSO, a known inhibitor of GSH synthesis, as described before
[24]. Briefly, cells were treated with 100 mM BSO (dissolved in
culture medium) for 18 h and washed with fresh serum free
DMEM followed by aspirin treatment as above. At this
concentration and time point, BSO alone has no significant effect
on HepG2 cell viability (data not shown). In another set of
experiments, ASA treatments (5 or 10 mmol/ml ASA 48 h) were
performed in GSH-depleted cells (BSO treatment for 18 h) which
were then treated with 10 mM NAC (dissolved in DMSO, then
diluted with cell culture medium to the required concentration
keeping the DMSO concentration not more than 0.1%) for 2 hr
before the addition of ASA for 48 h to manipulate cellular GSH
pools. Control cells were treated with vehicle alone (final DMSO
concentration not more than 0.1% which has no significant effect
on cellular functions and viability). After the desired time of
treatment, cells were harvested, washed with PBS (pH 7.4) and
homogenized in H-medium buffer (70 mM sucrose, 220 mM
mannitol, 2.5 mM HEPES, 2 mM EDTA and 0.1 mM phenyl-
methylsulfonylfluoride, pH 7.4) at 4uC. Mitochondria and post
mitochondrial (PMS) fractions were prepared by centrifugation
and the purity of the isolated fractions was checked for cross
contamination as described before [23].
Measurement of GSH concentration
HepG2 cells were treated with BSO and/or NAC as described
above and then exposed to different concentrations of ASA for
48 h. Sub cellular GSH levels in the mitochondria and PMS were
measured by the NADPH-dependent GSSG-reductase catalyzed
conversion of GSSG to GSH as described before [23], [25].
ROS measurement and apoptosis by flow cytometry
The intracellular production of ROS was measured using the
cell permeable probe DCFDA, which preferentially measures
peroxides. Briefly, GSH-depleted cells (,2610
6 cells/ml) treated
with ASA with or without NAC were incubated with 5 mM
DCFDA for 30 minutes at 37uC. Cells were washed twice with 16
PBS, trypsinized and resuspended in 3 ml of PBS and the
fluorescence was immediately read on a Becton Dickinson
FACScan with Cell Quest software (BD Biosciences, San Jose,
USA).
The apoptosis assay using flow cytometry was performed
according to the vendor’s protocol (BD Pharmingen, BD
Biosciences, San Jose, USA). Briefly, GSH-depleted cells treated
with ASA with or without NAC were trypsinized, washed in PBS
and resuspended (1610
6 cells/ml) in binding buffer (10 mM
HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). A fraction
(100 ml/1610
5 cells) of the cell suspension was incubated with 5 ml
Annexin V conjugated to FITC and 5 ml propidium iodide (PI) for
15 mins at 25uC in the dark. 400 ml of binding buffer was added to
the suspension and apoptosis was measured immediately using a
Becton Dickinson FACScan analyzer. The apoptotic cells were
estimated by the percentage of cells that stained positive for
Annexin V-FITC while remaining impermeable to PI (AV+/PI2).
This method was also able to distinguish viable cells (AV2/PI2)
and cells undergoing necrosis (AV+/PI+).
Measurement of DNA laddering
HepG2 cells were seeded on to 35 mm diameter culture dishes.
After allowing a 24 h period for attachment, GSH-depleted cells
were treated with 5 or 10 mmol/ml ASA for 48 h and NAC in
some cases as described above. Total DNA was isolated and
separated on 1.5% agarose gel. DNA fragmentation was visualized
Aspirin-Induced Mitochondrial Dysfunction
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separated fragments with 0.5 mg/ml ethidium bromide as
described before [23].
Measurement of GSH metabolism
HepG2 cells were treated with BSO with or without NAC as
described above and then exposed to different concentrations of
ASA for 48 h. Glutathione S-transferase (GST) activity using
CDNB and glutathione peroxidase (GSH-Px) activity using
cumene hydroperoxide as respective substrates were measured
by standard protocols as described before [25].
Measurement of lipid peroxidation
NADPH-dependent-membrane lipid peroxidation in ASA
treated cells after BSO/NAC treatment was measured as
thiobarbituric acid reactive substances (TBARS) using malone-
dialdehyde as standard as described previously [23].
Assay of caspase-3 activity
GSH depleted HepG2 cells with or without NAC (2610
6 cells/
well) were treated with different concentrations of ASA as
described above and the caspase-3 substrate, DEVD-pNA was
used to assay the protease activity colorimetrically as described in
the vendor’s protocol (R & D Systems).
Measurement of mitochondrial membrane potential
(MMP)
GSH depleted HepG2 cells with or without NAC (2610
6 cells/
well) were treated with different concentrations of ASA as
described above. The mitochondrial membrane potential was
measured by flow cytometry using a fluorescent cationic dye
according to the vendor’s protocol (DePsipher
TM, R &D System
Inc.) as described before [23]. DePsipher has the property of
aggregating upon membrane polarization forming an orange-red
fluorescent (absorption/emission 585/590 nm) compound. If the
membrane potential is reduced, the dye cannot access the
transmembrane space and remains in its green fluorescent (510/
527 nm) monomeric form.
Measurement of ATP level
HepG2 cells were treated with different concentrations of ASA
alone or after manipulation of GSH concentration by BSO with or
without NAC as described above. The ATP content in the cell
lysate was determined using ATP Bioluminescent cell assay kit
according to the manufacturer’s suggestion (Sigma, St Louis, MO)
and samples were read using the TD-20/20 Luminometer (Turner
Designs, Sunnyvale, CA).
Measurement of mitochondrial respiratory functions
Freshly isolated mitochondria (5 mg protein) from GSH
depleted with or without NAC treated HepG2 cells were
suspended in 1.0 ml of 20 mM KPi buffer, pH 7.4, in the
presence of the detergent, lauryl maltoside (0.2%). NADH-
ubiquinone oxidoreductase (complex I), and cytochrome c oxidase
(complex IV) were measured using the substrates coenzyme Q2
and reduced cytochrome c, respectively, by the methods of Birch-
Machin and Turnbull [26] as described before [23].
Mitochondrial aconitase activity was measured by NADPH
coupled conversion of citrate to isocitrate in the presence of
isocitrate dehydrogenase using the Bioxytech Aconitase-340 assay
kit. Aconitase activity was calculated according to the rate of
formation of NADPH at 340 nm.
Measurement of the expression of proteins by SDS-
PAGE/Western Blotting and immunofluorescence
microscopy
Proteins (50 mg) from the different sub cellular fractions of
control and treated cells were separated on 12% SDS-PAGE and
electrophoretically transferred onto nitrocellulose paper by
Western blotting using the standard procedures of Laemmli [27]
and Towbin et al. [28] as described before [23]. The immunor-
eacting protein bands were visualized after interacting with
primary antibodies against cytochrome c, caspase-3, PARP,
GSTA4-4 and Bcl-2. The expression of b-actin and Tom-40
proteins were used as respective house-keeping loading controls for
post-mitochondrial supernatant and mitochondrial fractions.
Densitometric analysis of the immunoreactive protein bands was
performed using the gel documentation system (Vilber Lourmat,
France) and expressed as relative intensity (R.I) compared to the
untreated control.
For immunofluorescence microscopy, HepG2 cells (2.5610
3)
were grown on cover slips in 6-well plates and were treated with
desired doses of ASA after treatment with BSO with or without
NAC. Cells were then fixed in 1% paraformaldehyde in PBS and
permeabilized with 0.1% Triton X-100 in PBS for 10 mins. Cells
were then blocked with 5% goat serum for 1 h at R.T and stained
with 1:300 dilution of anti-GST A4-4 polyclonal antibody
overnight at 4uC, followed by incubation with FITC-conjugated
secondary antibody for 1 h at room temperature as described
before [29]. Cover slips were then mounted on to glass slides and
examined and photographed using an Olympus microscope with
epifluorescence optics and interference filters.
Statistical analysis
Values shown are expressed as mean 6 SEM of three
determinations. Statistical significance of the data was assessed
by analysis of variance (ANOVA) followed by Tukey’s post-hoc
test and p values#0.05 were considered statistically significant.
Results
Aspirin-induced alterations in GSH pool
Our recent study on dose- and time-dependent effects of ASA
has shown that the low therapeutic doses of ASA exhibited no
significant effect on cell viability. ASA treatment at 5 mmol/ml
caused only 10–15% inhibition in cell viability while 10 mmol/ml
ASA caused about 30–40% loss in cell viability in 48 hours [23].
Selection of doses and time points in the present study was based
on these results and data from other published reports [8], [12],
[13]. In the present study, we have shown that low dose of ASA
(5 mmol/ml) caused no significant effect on GSH pool in the PMS
(Figure 1A) in HepG2 cells while 10 mmol/ml ASA caused a
significant reduction (Figure 1B). On the other hand, a marked
reduction (30–40%) in the mitochondrial GSH pool was observed
under these conditions (Figure 1A and Figure 1B). BSO treatment,
which inhibits the rate limiting enzyme for GSH synthesis, resulted
in almost 80% reduction in extra mitochondrial GSH concentra-
tion compared to about 50% reduction in the mitochondrial GSH
pool suggesting that cytosolic GSH is more sensitive to BSO
compared to mitochondrial GSH. ASA treatment did not reduce
the total GSH pools any further. NAC treatment, however,
resulted in partial recovery of mitochondrial GSH pool while
almost a complete recovery in the cytosolic GSH pool was
observed. This suggests an increased sensitivity of mitochondrial
GSH towards ASA treatment.
Aspirin-Induced Mitochondrial Dysfunction
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As shown in Figure 2 (i), the apoptosis assay by flow cytometry
has demonstrated that increasing doses of ASA treatment in GSH-
depleted cells caused increased apoptosis in HepG2 cells. When
compared with the control (which exhibited about 14% sponta-
neous apoptosis), low dose (5 mmol/ml) of ASA showed a 49%
increase in apoptosis in GSH-depleted cells while 10 mmol/ml
ASA caused 68% increase in apoptosis after 48 h. NAC treatment,
however, caused only moderate recovery of aspirin-induced
apoptosis in HepG2 cells suggesting additional factor(s), other
than altered GSH pool, which could play a role in inducing
apoptosis by ASA. A histogram showing net increase in apoptosis
after subtraction of cell death caused by GSH depletion in control
cells is shown in Figure 2(ii).
Aspirin-induced ROS production
Using DCFDA as a fluorescent probe, we observed a significant
increase (almost 2–2.5 fold) in ROS production in GSH-depleted
cells after 5 mmol/ml and 10 mmol/ml ASA treatments (Figure 3 i
and ii). NAC treatment brought the level of ROS close to control
level in 5 mmol/ml ASA treated cells while only partial recovery
was observed in cells treated with 10 mmol/ml ASA. These results
further suggest that GSH plays only a partial role in the regulation
of ROS production in ASA treated HepG2 cells.
Aspirin-induced DNA fragmentation
As shown in Figure 4, increased DNA fragmentation in GSH-
depleted HepG2 cells was observed after ASA treatment (lane 2
and 3). NAC treatment appears to have partially protected the
breakdown of DNA which was more apparent with 5 mmol/ml
(lane 4) compared to 10 mmol/ml ASA (lane 5) treated cells.
Aspirin-induced alterations in GSH metabolism
GSH-Px activity in HepG2 cells was significantly increased after
ASA treatment (Figure 5A and B).The enzyme activity was further
increased (40%) in GSH-depleted- 5 mmol/ml ASA treated cells
and almost 2-fold in GSH-depleted 10 mmol/ml ASA treated cells
in the PMS while mitochondria showed only 15–30% increased
activity in GSH-depleted cells. NAC treatment, however, showed
only partial recovery of the enzyme activity.
Total GST activity using CDNB as substrate was significantly
increased in HepG2 cells after ASA treatment (Figure 6A and 6B).
The enzyme activity was further increased in GSH depleted cells
treated with ASA. NAC treatment brought the enzyme activity
close to control values in 5 mmol/ml ASA treated cells (Figure 6A)
but not in 10 mmol/ml ASA treated cells, where the enzyme
activity remained significantly higher (Figure 6B). These results
were further confirmed by SDS-PAGE and immunofluorescence
studies on the expression of GST A4-4 protein using isoenzyme
specific antibody as described later.
Aspirin-induced increase in LPO
ASA treatment caused a significant increase in LPO (Figure 7A,
B). It was further increased in GSH-depleted cells treated with
ASA. NAC treatment resulted in complete recovery of LPO in
Figure 1. Aspirin-induced alterations in the GSH pool. HepG2 cells were treated with 5 mmol/ml (Figure 1A) and 10 mmol/ml (Figure 1B) of
ASA for 48 h and GSH levels in the mitochondria and post mitochondrial supernatant (PMS) were measured by enzymatic method as described in the
Materials and Methods. Results are expressed as mean 6 SEM of three determinations. Figure also represents measurement of GSH levels after
treatment of cells with 100 mM BSO for 18 h alone or after treatment with 10 mM NAC for 2 h prior to the ASA treatment. The values are expressed as
mean 6 SEM of three determinations. Asterisks (*) indicate significant difference (P#0.05) from control values, # indicate significant difference
(P#0.05) from ASA treated group and d indicate significant difference (P#0.05) as compared to BSO+ASA treated group.
doi:10.1371/journal.pone.0036325.g001
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treated cells exhibited only partial recovery (Figure 7B).
Aspirin-induced caspase-3 activation
ASA treatment caused a significant increase in caspase-3 activity
with 10 mmol/ml ASA compared to 5 mmol/ml ASA (Figure 8 A,
B). The enzyme activity remained markedly increased after ASA
treatment in GSH depleted cells. NAC treatment, on the other
hand, brought the enzyme activity to the level of control untreated
cells. These results have further confirmed the increased apoptosis
and DNA fragmentation observed (Figure 2 and 4) after ASA
treatment in GSH depleted cells and further established the
protective effect of NAC from drug induced apoptosis.
Aspirin-induced reduction in mitochondrial membrane
potential (MMP)
A significant loss (2–4 fold) in mitochondrial membrane
potential was observed after ASA treatment in GSH depleted
cells (Figure 9 i and ii).The effect of ASA appeared to be dose
dependent. NAC treated cells, however, showed partial recovery
from ASA-affected MMP, suggesting only partial protection of
mitochondrial membrane permeability by GSH pool.
Aspirin-induced mitochondrial dysfunction
Effect on ATP level. ASA caused a significant decrease in
cellular ATP level with increasing dose (Figure 10A, B). GSH
depletion in ASA treated cells further reduced the level of ATP.
NAC treatment exhibited partial recovery from ATP depletion in
GSH-depleted cells.
Effect on the mitochondrial matrix enzyme,
aconitase. The mitochondrial matrix enzyme, aconitase, was
also markedly inhibited by ASA treatment. The effect on the
enzyme activity appeared to be dose dependent (Figure 11A, B).
GSH depletion prior to ASA treatment resulted in further
inhibition of aconitase activity. NAC treatment, however,
showed no recovery in GSH depleted treated cells.
Effect of ASA on respiratory functions. Only a marginal
inhibition of Complex I activity was observed after ASA
treatment. On the other hand, a significant inhibition (,50%) in
Complex IV (cytochrome c oxidase) activity was observed after
ASA treatment (Figure 12 A, B). Complex I activity inhibition by
ASA was more pronounced (almost 50%) in GSH-depleted cells
while NAC treatment caused complete recovery of the enzyme
activity. Similarly, the inhibitory effect of ASA on Complex IV
activity was more pronounced in GSH-depleted cells. Unlike its
Figure 2. Aspirin-induced apoptosis. Apoptosis in GSH depleted and NAC treated HepG2 cells were measured after ASA treatment using Flow
cytometry (Figure 2i) as described in the vendor’s protocol using the Becton Dickinson FACScan analyzer. Apoptotic cells were estimated by the
percentage of cells that stained positive for Annexin V-FITC. Histogram showing the percentage increase in apoptosis after ASA and NAC treated
GSH-depleted cells is shown in Figure 2ii. # indicate significant difference (P#0.05) from 5 mmol/ml ASA treated group and d indicate significant
difference (P#0.05) as compared to 10 mmol/ml ASA treated group.
doi:10.1371/journal.pone.0036325.g002
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e36325Figure 3. Aspirin-induced ROS production. Intracellular production of ROS was measured using DCFDA and fluorescence was measured by flow
cytometry using Cell Quest software as described in the Materials and Methods. ROS was measured in GSH depleted HepG2 cells treated with
different concentrations of aspirin and also after NAC treatment (Figure 3i). Result expressed is a typical representation of three determinations.%
change in ROS production from a typical histogram is presented in Figure 3ii. Asterisks indicate significant difference (P#0.05) from control values, #
indicate significant difference (P#0.05) from 5 mmol/ml ASA treated group and d indicate significant difference (P#0.05) as compared to 10 mmol/ml
ASA treated group.
doi:10.1371/journal.pone.0036325.g003
Figure 4. Aspirin-induced DNA fragmentation. DNA was isolated from GSH-depleted and NAC treated cells after treatment with different doses
of ASA as described in the Materials and Methods. DNA fragmentation was studied using 1.5% agarose gel electrophoresis and visualized by ethidium
bromide staining. A 1000 base pair DNA ladder was used as marker. A typical result from three experiments has been shown here.
doi:10.1371/journal.pone.0036325.g004
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oxidase activity in GSH-depleted cells treated with 10 mmol/ml
ASA suggesting higher sensitivity of the enzyme towards ASA/
GSH-depletion.
Aspirin-induced expression of apoptotic markers. As
shown in Figure 13a, ASA treatment in GSH-depleted cells
reduced the level of cytochrome c in the mitochondria. The
translocation of cytochrome c from the mitochondria was more
apparent after treatment with 10 mmol/ml ASA. The release of
cytochrome c from the mitochondria, in turn, resulted in
activation of caspase-3 (Figure 13b). This in turn, was
accompanied by activation of PARP, suggesting the activation of
DNA repair mechanism and apoptotic signals in ASA treated cells.
The expression of the antiapoptotic protein, Bcl-2 was also
inhibited in GSH-depleted ASA treated cells. All these results
suggest activation of the apoptotic process in HepG2 cells after
ASA treatment. NAC treatment, however, resulted in partial
recovery of the apoptotic markers described above suggesting
partial protection from the deleterious effects of the drug.
Immunocytochemical studies on the expression of
GSTA4-4. Figure 14a shows an increased expression
(immunofluorescence) of GSTA4-4, an oxidative stress specific
GST isoenzyme, in HepG2 cells after ASA treatment.NAC
treatment brought the enzyme activity close to control values in
Figure 5. Aspirin-induced alterations in GSH Peroxidase. GSH-peroxidase (Figures 5A, B) was measured in GSH-depleted cells after treatment
with different concentrations of ASA and NAC as described in the Materials and Methods. The values are expressed as mean 6 SEM of three
determinations. Asterisks indicate significant difference (P#0.05) from control values, # indicate significant difference (P#0.05) from ASA treated
group and d indicate significant difference (P#0.05) as compared to BSO+ASA treated group.
doi:10.1371/journal.pone.0036325.g005
Figure 6. Aspirin-induced alterations in GST. GST activity (Figures 6 A, B) was measured in GSH-depleted cells after treatment with different
concentrations of ASA and NAC using CDNB as substrate as described in the Materials and Methods. The values are expressed as mean 6 SEM of
three determinations. Asterisks indicate significant difference (P#0.05) from control values, # indicate significant difference (P#0.05) from ASA
treated group and d indicate significant difference (P#0.05) as compared to BSO+ASA treated group.
doi:10.1371/journal.pone.0036325.g006
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cells, where the enzyme expression remained significantly higher.
The increased expression of GSTA4-4 was also confirmed by
Western blot analysis as shown in Figure 14b.
Discussion
Epidemiological and experimental studies have reported anti-
inflammatory, anticancer and antidiabetic effects of NSAIDs. The
molecular mechanism(s) by which aspirin and other NSAIDs exert
their anticancer effects, however, is still not clear. In addition to
the inhibition of arachidonic acid metabolism by COX inhibition,
other possible mechanisms for the multiple effects of ASA include
increased ROS production, alterations in mitochondrial function,
cell signaling and induction of apoptosis [7], [19], [30], [31], [32],
[33]. Although in this study and in our previous study [23] on
HepG2 cells, we have used ASA to elucidate COX-independent
mechanisms of drug action, there are reports that suggest that
salicylate, an active metabolite of aspirin, has more or less similar
mechanisms of action on mitochondrial-induced apoptosis [30],
[31]. We have reported previously that ASA induces cell cycle
arrest, mitochondrial dysfunction and oxidative stress in HepG2
Figure 7. Aspirin-induced LPO. Membrane LPO was determined in GSH-depleted cells after treatment of ASA and NAC (Figures 7A, B) as
described in the Materials and Methods. The values are expressed as mean 6 SEM of three determinations. Asterisks indicate significant difference
(P#0.05) from control values, # indicate significant difference (P#0.05) from ASA treated group and d indicate significant difference (P#0.05) as
compared to BSO+ASA treated group.
doi:10.1371/journal.pone.0036325.g007
Figure 8. Aspirin induced caspase-3 activity. Caspase-3 activity in HepG2 cells treated with aspirin and after manipulation of GSH levels by BSO
and NAC was measured using DEVD peptide conjugated to p-nitroanaline as described in the vendor’s protocol (Figures 8A, B). The values are
expressed as mean 6 SEM of three determinations. Asterisks indicate significant difference (P#0.05) from control values while d indicate significant
difference (P#0.05) as compared to BSO+ASA treated group.
doi:10.1371/journal.pone.0036325.g008
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PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e36325Figure 9. Aspirin-induced disruption in mitochondrial membrane potential. GSH-depleted HepG2 cells were treated with different
concentrations of aspirin and membrane potential was measured using a cationic fluorescent dye as described in the Materials and Methods.
Mitochondrial membrane potential was also measured after manipulation of GSH levels by NAC treatment. Figure 9i is a representative of three
individual experiments. Figure 9ii is a typical histogram showing % loss of mitochondrial membrane potential. Asterisks indicate significant difference
(P#0.05) from control values, # indicate significant difference (P#0.05) from 5 mmol/ml ASA treated group and d indicate significant difference
(P#0.05) as compared to 10 mmol/ml ASA treated group.
doi:10.1371/journal.pone.0036325.g009
Figure 10. Aspirin-induced alteration in ATP level. HepG2 cells were treated with different concentrations of aspirin after BSO/NAC treatment
and ATP content was measured in the total cell lysate (Figures 10A, B) using the ATP Bioluminescent somatic cell assay kit as described in the
Materials and Methods. The values are expressed as mean 6 SEM of three determinations. Asterisks indicate significant difference (P#0.05) from
control values, # indicate significant difference (P#0.05) from ASA treated group and d indicate significant difference (P#0.05) as compared to
BSO+ASA treated group.
doi:10.1371/journal.pone.0036325.g010
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e36325Figure 11. Aspirin-induced alteration in aconitase activity. The HepG2 cells were treated with different concentrations of aspirin and
aconitase activity was measured after the manipulation of GSH level by BSO or NAC (Figures 11A, B) as described in the Materials and Methods. The
values are expressed as mean 6 SEM of three determinations. Asterisks indicate significant difference (P#0.05) from control values, # indicate
significant difference (P#0.05) from ASA treated group and d indicate significant difference (P#0.05) as compared to BSO+ASA treated group.
doi:10.1371/journal.pone.0036325.g011
Figure 12. Aspirin-induced alterations in mitochondrial Complex I and Complex IV activities. Freshly isolated mitochondria from control
and aspirin treated HepG2 cells after BSO/NAC treatments were used to assay Complex I and cytochrome c oxidase activity as described in the
Materials and Methods. (Figures 12A, B). The values are expressed as mean 6 SEM of three determinations. Asterisks indicate significant difference
(P#0.05) from control values, # indicate significant difference (P#0.05) from ASA treated group and d indicate significant difference (P#0.05) as
compared to BSO+ASA treated group.
doi:10.1371/journal.pone.0036325.g012
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PLoS ONE | www.plosone.org 10 April 2012 | Volume 7 | Issue 4 | e36325cells [23]. The increased apoptosis observed was presumably
initiated by the altered mitochondrial membrane potential causing
release of cytochrome c and activation of the intrinsic apoptotic
pathway. ASA also caused dose and time-dependent increase in
ROS production and decrease in GSH pool. Mitochondrial GSH
pool homeostasis has been shown to be closely coupled with Bcl-2
translocation and apoptosis [34], [35], [36]. Our study had shown
a marked initial depletion in mitochondrial GSH pool by aspirin.
However, it was not clear how ASA exerts its multiple effects in
oxidative stress conditions when cellular GSH pool is altered
(depleted or enhanced). Therefore, in the present study, we
investigated the effect of ASA on HepG2 cells after treating the
cells with BSO, a GSH synthesis inhibitor and NAC, a GSH
synthesis precursor. We observed that GSH depletion in HepG2
cells by BSO selectively inhibited cytosolic GSH pool in
comparison to the mitochondrial GSH pool. This is presumably
due to the fact that mitochondria do not have a GSH synthesizing
enzyme system and depend upon the energy/transporter-depen-
dent transfer of GSH from the cytosol [37]. Our results in the
present study show that ASA-induced mitochondrial dysfunction
and oxidative stress were further augmented in GSH-depleted
cells, while NAC treatment attenuated the effects of aspirin in
GSH-depleted cells. Our study has also shown that the effect of
NAC on ASA treatment in GSH-depleted cells was selective in
terms of recovery of GSH metabolism and oxidative stress in
different cellular compartments and on mitochondrial functions
and apoptosis. The recovery of respiratory Complex I activity and
membrane potential was significant after NAC treatment while
that of ATP synthesis and activities of Complex IV and the matrix
enzyme, aconitase was negligible in GSH-depleted cells. ROS
production was high in GSH-depleted cells even after NAC
treatment suggesting recovery in membrane potential after NAC
treatment may partially be independent of ROS production and
GSH pool in mitochondria. GSH depletion in HepG2 cells
augmented LPO and NAC treatment resulted in partial protection
from LPO suggesting the protective role of mitochondrial GSH
metabolism in membrane lipid peroxidation. Increased GSH-Px
activity observed after ASA treatment might be a protective
mechanism to increase ROS clearance and protect vital cellular
functions from oxidative stress associated complications. Similarly,
GSH-conjugation/detoxification (including ROS) activity by
GST, which also has GSH-peroxidase activity, is increased by
ASA in GSH-depleted cells. We have previously shown increased
expression and activities of GSTs in oxidative stress conditions.
We have also shown that GSTA4-4 was specifically induced in
oxidative stress conditions [25], [29], [37], [38]. In the present
study also, using SDS-PAGE and immunofluorescence microsco-
py, we have confirmed the increased expression of GSTA4-4 in
GSH-depleted cells treated with ASA. NAC treatment resulted in
partial decrease in GSTA4-4 expression. NAC treatment also
resulted in partial protection of apoptosis as observed by the
reduced cytochrome c release from mitochondria and reduced
activation of caspase-3 and PARP hydrolysis.
In confirmation of our previous study [23], in the present study
also, we observed that alterations in the GSH pool altered the
mitochondrial bioenergetics in ASA treated cells. ASA caused a
Figure 13. Expression of apoptotic markers. Proteins (50 mg) from PMS or mitochondrial extract from ASA/NAC treated GSH-depleted HepG2
cells were separated on 12% SDS-PAGE and transferred on to nitrocellulose paper by Western blotting as described in the Materials and Methods. The
visualization of cytochrome c (Figure 13a) and Bcl-2, PARP and caspase-3 (Figure 13b) was made by using specific antibodies against these proteins.
Beta-actin and Tom-40 were used as respective loading controls for post-mitochondrial supernatant and mitochondria. Figure is a typical result
obtained from three independent experiments. The quantitation of proteins bands are expressed as relative intensity (R.I) of the upper band using
expression of proteins in control untreated cells as 1.0. Molecular weight markers (kDa) are indicated by arrows.
doi:10.1371/journal.pone.0036325.g013
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PLoS ONE | www.plosone.org 11 April 2012 | Volume 7 | Issue 4 | e36325marked decrease in ATP level in GSH-depleted cells. The reduced
ATP level in ASA treated cells was dose dependent. The decrease
in ATP production by ASA was accompanied by inhibition in the
activities of respiratory chain enzymes particularly, cytochrome c
oxidase (Complex IV) and the mitochondrial matrix enzyme,
aconitase. These enzymes determine the rate of mitochondrial
oxygen utilization, ROS production, oxidative stress and ATP
synthesis [15], [16], [39], [40], [41], [42], [43], [44]. Recently, it
has been shown that mitochondrial GSH pool and expression of
antiapoptotic protein Bcl-2 are directly involved in the regulation
of mitochondrial membrane potential, redox and respiratory
functions [36], [45]. Our results have also shown a decrease in Bcl-
2 expression after ASA treatment which was augmented in GSH
depleted cells and attenuated after NAC treatment. The precise
mechanisms by which GSH depletion regulates apoptosis are,
however, not clear. Studies have suggested that HepG2 cells
undergoing apoptosis have greater loss of intracellular GSH due to
increased export of GSH to extracellular space [46]. A recent
study has also suggested that depletion of GSH regulates apoptosis
independent of excessive ROS production [47]. Therefore,
maintenance of intracellular GSH levels during apoptosis provides
protection to the cell by multiple mechanisms. NAC, a thiol
antioxidant, is increasingly used in clinical trials of chemotherapy
and as a chemoprotectant in drug-induced toxicity [48]. In our
study, the marked reduction of ATP level in GSH depleted cells
was attenuated by NAC treatment. This observation was further
supported by the recovery in Complex I activity in ASA treated
cells in the presence of NAC. However, NAC treatment could not
completely recover all the mitochondrial respiratory functions as
the activities of cytochrome c oxidase and aconitase remained
inhibited in the drug treated cells even after NAC treatment. This
suggests that mitochondrial GSH is selectively involved in
regulating the activities of the respiratory complexes. The
inhibitory effect of ASA on cytochrome c oxidase and aconitase
activities was more apparent in GSH depleted cells. Our previous
studies, using in vitro cell culture as well as in vivo animal models
have also demonstrated that enzymes cytochrome c oxidase
(Complex IV) and aconitase are extremely sensitive to mitochon-
drial-ROS induced oxidative stress in comparison to other
complexes [23],[38],[42],[43]. This differential sensitivity of
respiratory complexes might be attributed to their responses
towards oxidative stress, ROS, NO, and glutathionylation of
proteins. Reversible glutathionylation of Complex I in response to
oxidation of mitochondrial GSH pool has been shown to increase
ROS formation [49]. Recovery of Complex I activity by NAC in
our study might therefore be due to the decrease in oxidative
glutathionylation of the protein. On the other hand, Complex IV
activity has been reported to be reversibly inhibited by NO that
increases superoxide production in mitochondria [50], [51].
Recent studies have shown that increased ROS production
promotes reversible uncoupling of NO synthase (NOS) and
shifting the enzyme activity to produce more ROS instead of
NO [51], [52]. This uncoupling disrupts the cross-talk between
ROS-generating enzymes and redox-cell signaling affecting the
activities of respiratory complexes. Our recent study, on
acetaminophen-induced toxicity in macrophages has also suggest-
ed that differential inhibition of mitochondrial respiratory enzymes
is associated with altered ROS/NO homeostasis in mitochondria
[53].Our recent publications have also discussed extensively the
mitochondrial respiratory dysfunctions under increased oxidative
stress conditions [23], [25], [38], [42], [43]. NAC does not seem to
be involved in complete protection of mitochondrial respiratory
Figure 14. Immunocytochemical localization of GST A4-4. HepG2 cells were grown on cover slips and treated with ASA after GSH depletion
with or without NAC as described in the Materials and Methods. Cells were then fixed in 1% paraformaldehyde and permeabilised in 0.1% Triton X-
100. Cells were incubated with 1:300 dilution of GST A4-4 antibody followed by FITC-conjugated secondary antibody. Cover slips were then examined
and photographed using an Olympus fluorescent microscope (Figure 14a). Immunoblotting was carried out using GSTA4-4 specific polyclonal
antibody (Figure 14b). The quantitation of the protein bands are expressed as relative intensity (R.I) compared to the control untreated cells as 1.0.
Molecular weight marker (kDa) is indicated by an arrow. b-actin was used as a loading control.
doi:10.1371/journal.pone.0036325.g014
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PLoS ONE | www.plosone.org 12 April 2012 | Volume 7 | Issue 4 | e36325functions in HepG2 cells from ASA-induced toxicity under these
conditions. A similar observation with NAC treatment was also
made when HepG2 cells were treated with acetaminophen [54].
These results clearly demonstrate that mitochondrial integrity and
some of the key mitochondrial respiratory functions are indeed
regulated by the antioxidant GSH pool and that they are potential
selective targets for ASA- induced toxicity.
In summary, we have demonstrated that GSH depletion
augmented the effects of ASA on mitochondrial functions and
apoptosis in HepG2 cells by altering membrane potential,
oxidative stress and activities of the respiratory chain enzymes.
In addition, we have also shown that NAC plays a protective role,
at least in part, in maintaining the GSH-dependent redox
homeostasis and integrity of the mitochondrial functions. The
expression of apoptotic signals also appears to be linked to
alterations in the GSH pool. Therefore, a distinct outcome of the
manipulation in GSH pool might be significant in therapeutic
management of cancer and other inflammatory disorders. Our
study suggests that manipulation of GSH homeostasis in HepG2
cells might have implications in ASA-induced sensitization of
cancer cells which are potentially important in increasing the
efficacy of anti-inflammatory chemotherapeutic drugs in inducing
targeted apoptosis.
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